Search Results for "Diabetes"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Diabetes. Results 91 to 100 of 105 total matches.
Inclisiran (Leqvio) for LDL-Cholesterol Lowering
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022 (Issue 1646)
(type 2 diabetes, familial
hypercholesterolemia, or a 10-year risk of a cardiovascular event of
≥20 ...
The FDA has approved inclisiran (Leqvio – Novartis),
a small interfering RNA (siRNA) directed to proprotein
convertase subtilisin/kexin type 9 (PCSK9) mRNA,
as an adjunct to diet and maximally tolerated statin
therapy for subcutaneous (SC) treatment of adults
with heterozygous familial hypercholesterolemia
(HeFH) or clinical atherosclerotic cardiovascular
disease (ASCVD) who require additional lowering
of low-density lipoprotein cholesterol (LDL-C).
Inclisiran is the first FDA-approved PCSK9-directed
siRNA therapeutic agent.
A Three-Antigen Hepatitis B Vaccine (PreHevbrio)
The Medical Letter on Drugs and Therapeutics • May 16, 2022 (Issue 1650)
., injection drug users; persons with diabetes or on
maintenance dialysis; healthcare personnel)
Planning ...
The FDA has licensed PreHevbrio (VBI Vaccines), a
recombinant, 3-antigen, 3-dose hepatitis B vaccine,
for the prevention of infection caused by all known
subtypes of hepatitis B virus (HBV) in adults. It has
been available in Israel since 2000.
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • May 27, 2024 (Issue 1703)
risk of ≥10%,1 or have
diabetes, chronic kidney disease (CKD), or heart failure.
Patients ...
American College of Cardiology/American Heart
Association (ACC/AHA) guidelines for treatment of
hypertension were last published in 2018. Treatment
of hypertensive urgencies and emergencies is not
discussed here.
Med Lett Drugs Ther. 2024 May 27;66(1703):81-8 doi:10.58347/tml.2024.1703a | Show Introduction Hide Introduction
Influenza Vaccine for 2024-2025
The Medical Letter on Drugs and Therapeutics • Sep 16, 2024 (Issue 1711)
In a prospective cohort study in
patients with diabetes, influenza vaccination was
associated with hyperglycemia ...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
available in the US for the 2024-2025 season are
listed in Table 2.
Med Lett Drugs Ther. 2024 Sep 16;66(1711):145-50 doi:10.58347/tml.2024.1711a | Show Introduction Hide Introduction
Two New Pneumococcal Vaccines - Prevnar 20 and Vaxneuvance
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021 (Issue 1638)
conditions include alcohol use disorder, chronic heart, liver, or lung disease, and diabetes mellitus.
190 ...
The FDA has licensed two new pneumococcal
conjugate vaccines (PCVs) for prevention of invasive
pneumococcal disease in adults: Prevnar 20 (PCV20;
Pfizer), which contains antigens from 20 serotypes of
pneumococcus, and Vaxneuvance (PCV15; Merck),
which contains antigens from 15 serotypes. Two
other pneumococcal vaccines are available in the
US: Prevnar 13 (PCV13; Pfizer), a 13-valent conjugate
vaccine licensed for use in persons ≥6 weeks old,
and Pneumovax 23 (PPSV23; Merck), a 23-valent
pneumococcal polysaccharide vaccine licensed for
use in persons ≥2 years...
Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
such as diabetes
Pregnancy and Lactation
Should not be used by breastfeeding women;
increased risk ...
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
Adult Immunization
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022 (Issue 1661)
Immunocompromising 3 10 X11,12 X11,12 13 14 RF RF 15
conditions8,9
(except HIV)
Diabetes 16 10 ...
The Advisory Committee on Immunization Practices
(ACIP) recommends use of certain vaccines in adults
residing in the US. Routine childhood immunization
has reduced the overall incidence of some of
these vaccine-preventable diseases, but many
adults remain susceptible. Recommendations for
vaccination against COVID-19, seasonal influenza,
and monkeypox and vaccination of travelers have
been reviewed separately.
Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
or cardiovascular diseases, moderate or severe
immune compromise, diabetes, neurologic or
neuromuscular conditions ...
Two recombinant vaccines, Arexvy (GSK) and
Abrysvo (Pfizer), have been approved by the FDA for
prevention of lower respiratory tract disease (LRTD)
caused by respiratory syncytial virus (RSV) in adults
≥60 years old. They are the first RSV vaccines to be
approved in the US. Abrysvo is also approved for
use in pregnant women at 32-36 weeks' gestation
to prevent LRTD caused by RSV in their infants from
birth through 6 months of age.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):155-6 doi:10.58347/tml.2023.1686a | Show Introduction Hide Introduction
Drugs for Hypothyroidism
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023 (Issue 1670)
.
13. B Biondi and AR Cappola. Subclinical hypothyroidism in older
individuals. Lancet Diabetes ...
Primary hypothyroidism is usually the result of
Hashimoto's (autoimmune) thyroiditis, thyroidectomy,
or radioactive iodine therapy. Treatment of
hypothyroidism with replacement doses of thyroid
hormone is usually lifelong. Levothyroxine (LT4;
synthetic thyroxine; Synthroid, and others) is the drug
of choice.1
Med Lett Drugs Ther. 2023 Feb 20;65(1670):25-9 doi:10.58347/tml.2023.1670a | Show Introduction Hide Introduction
Comparison Table: Some Drugs for HFrEF (online only)
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
with type 2 diabetes and established cardiovascular disease Ensure eGFR ≥30 mL/min/1.73 m2 for dapagliflozin ...
View the Comparison Table: Some Drugs for HFrEF